A federal court has upheld the validity of Novartis’ patent covering a dosing regimen for its blockbuster multiple sclerosis therapy, Gilenya (fingolimod), rejecting a challenge from Chinese drugmaker HEC Pharma.
Source: Drug Industry Daily